Journal: Frontiers in Molecular Biosciences

Article Title: Integrated network analysis and experimental validation identify CCNA2, CD44, and STAT1 as clinically relevant hub genes in oral squamous cell carcinoma

doi: 10.3389/fmolb.2026.1748821

Figure Lengend Snippet: Network-based hub gene screening and expression validation in OSCC. (A) Top 10 hub candidates ranked by betweenness centrality. (B) Top 10 hub candidates ranked by degree centrality. (C) Intersection of two rankings identifying CCNA2, CD44, and STAT1 as shared hub genes. (D–F) Expression of CCNA2, CD44, and STAT1 in GSE30784 . (G–I) Expression of CCNA2, CD44, and STAT1 in GSE9844 .

Article Snippet: Primary antibodies against Cyclin A2 (CCNA2) (Abcam, ab181973), Cluster of Differentiation 44 (CD44) (Cell Signaling Technology, #3570), and Signal Transducer and Activator of Transcription 1 (STAT1) (Proteintech, 10144-2-AP) were applied, followed by HRP-conjugated secondary antibodies and DAB detection with hematoxylin counterstaining.

Techniques: Expressing, Biomarker Discovery

Journal: Frontiers in Molecular Biosciences

Article Title: Integrated network analysis and experimental validation identify CCNA2, CD44, and STAT1 as clinically relevant hub genes in oral squamous cell carcinoma

doi: 10.3389/fmolb.2026.1748821

Figure Lengend Snippet: Validation and characterization of hub genes in TCGA cohort. (A–C) mRNA expression of CCNA2, CD44 and STAT1 in TCGA OSCC vs. normal tissues. (D–F) Kaplan–Meier overall survival curves stratified by CCNA2, CD44 and STAT1 expression. (G–I) GSEA enrichment plots for CCNA2, CD44 and STAT1.

Article Snippet: Primary antibodies against Cyclin A2 (CCNA2) (Abcam, ab181973), Cluster of Differentiation 44 (CD44) (Cell Signaling Technology, #3570), and Signal Transducer and Activator of Transcription 1 (STAT1) (Proteintech, 10144-2-AP) were applied, followed by HRP-conjugated secondary antibodies and DAB detection with hematoxylin counterstaining.

Techniques: Biomarker Discovery, Expressing

Journal: Frontiers in Molecular Biosciences

Article Title: Integrated network analysis and experimental validation identify CCNA2, CD44, and STAT1 as clinically relevant hub genes in oral squamous cell carcinoma

doi: 10.3389/fmolb.2026.1748821

Figure Lengend Snippet: Prognostic nomogram and diagnostic performance of CCNA2, CD44 and STAT1. (A) Nomogram model based on CCNA2, CD44 and STAT1. (B) Calibration curve of the nomogram for 1-year survival prediction. (C) ROC curves of CCNA2, CD44 and STAT1 in GSE30784 . (D) ROC curves of CCNA2, CD44 and STAT1 in GSE9844 . (E) ROC curves of CCNA2, CD44 and STAT1 in TCGA.

Article Snippet: Primary antibodies against Cyclin A2 (CCNA2) (Abcam, ab181973), Cluster of Differentiation 44 (CD44) (Cell Signaling Technology, #3570), and Signal Transducer and Activator of Transcription 1 (STAT1) (Proteintech, 10144-2-AP) were applied, followed by HRP-conjugated secondary antibodies and DAB detection with hematoxylin counterstaining.

Techniques: Diagnostic Assay

Journal: Frontiers in Molecular Biosciences

Article Title: Integrated network analysis and experimental validation identify CCNA2, CD44, and STAT1 as clinically relevant hub genes in oral squamous cell carcinoma

doi: 10.3389/fmolb.2026.1748821

Figure Lengend Snippet: Experimental validation of CCNA2, CD44 and STAT1 expression in OSCC tissues and cell lines. (A) Representative IHC staining of CCNA2, CD44 and STAT1 in control and OSCC tissues. (B–D) Quantification of IHC staining index for CCNA2, CD44 and STAT1 in human oral tissues. (E–G) qPCR analysis of CCNA2, CD44 and STAT1 mRNA levels in human oral tissues. (H–J) qPCR analysis of CCNA2, CD44 and STAT1 mRNA levels in normal versus OSCC cell lines. (K,L) qPCR analysis of CRNN mRNA expression in human oral tissues and cell lines. Data are presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.

Article Snippet: Primary antibodies against Cyclin A2 (CCNA2) (Abcam, ab181973), Cluster of Differentiation 44 (CD44) (Cell Signaling Technology, #3570), and Signal Transducer and Activator of Transcription 1 (STAT1) (Proteintech, 10144-2-AP) were applied, followed by HRP-conjugated secondary antibodies and DAB detection with hematoxylin counterstaining.

Techniques: Biomarker Discovery, Expressing, Immunohistochemistry, Control

Journal: Biomolecules & Therapeutics

Article Title: Novel Effect of Hyaluronan and Proteoglycan Link Protein 1 (HAPLN1) on Hair Follicle Cells Proliferation and Hair Growth

doi: 10.4062/biomolther.2023.080

Figure Lengend Snippet: Lack of endogenous CD44 decreased TβRII levels expression in HHGMCs. (A) The plot and the relative quantification of the expression of TβRII in CD44 following HAPLN1 knockdown. (B) The plot and the relative quantification of the expression of TβRII in CD44 knockdown HHGMCs pretreated with rhHAPLN1 (25 ng/mL) and/or HA (25 μg/mL) for 1 h prior to stimulation with TGF-β2 (2 ng/mL) for 23 h (n=3). * p <0.05, ** p <0.01 versus corresponding siCTL group.

Article Snippet: Small interference RNAs (siRNA) include siHAPLN1 (Dharmacon, Lafayette, CO, USA), negative control siRNA (siCTL; Dharmacon), Cluster of Differentiation 44 (CD44) siRNA (siCD44; Thermo Fisher Scientific), and negative control siRNA (siCTL; Thermo Fisher Scientific) were used at transfect to HHGMCs using Lipofectamine ® RNAiMAX (Thermo Fisher Scientific) in low serum medium for 24 h. The cells were harvested 24 h after transfection.

Techniques: Expressing, Quantitative Proteomics, Knockdown